Dividend Policy & Shareholder Returns
Dividend History: STTK is not an income stock – Shattuck Labs does not pay dividends (www.alphaspread.com). Since its 2020 IPO, the company has retained all capital to fund R&D rather than returning cash to shareholders. The current trailing 12-month dividend payout is $0.00 (www.macrotrends.net), and no dividends are expected in the foreseeable future. This is typical for clinical biotechs, which operate at a net loss and prioritize drug development over shareholder payouts. Investors in STTK should not expect income; rather, the appeal is the potential for capital gains if the company’s drug candidates succeed.
Buybacks: Similarly, Shattuck has no share repurchase program – instead it has issued equity to raise funds. In fact, 2025 saw substantial equity financing (discussed below) which diluted existing shareholders but bolstered the balance sheet. Thus, Shattuck’s shareholder yield (dividends + buybacks + debt paydown) is effectively zero, reflecting a strategy of reinvestment over capital return. Management’s stance is to create value through advancing the pipeline, not via financial engineering at this stage.
Q4 & FY2025 Financial Performance
Operating Results: Shattuck’s full-year 2025 results highlight drastically reduced operating expenses after the strategic realignment. Research & Development expenses in 2025 were $35.3 million, nearly halved from 2024’s $67.2 million (www.biospace.com). In Q4 2025, R&D was $9.1 million (vs $15.4 M in Q4 2024) (www.biospace.com). This sharp decline was mainly due to winding down the SL-172154 oncology program and related headcount cuts, partially offset by increased spending on SL-325 as it entered clinical trials (www.biospace.com) (www.globenewswire.com). General & Administrative expenses were $17.2 million for 2025, slightly down from $19.1 million in 2024 (www.biospace.com), thanks to lower compensation and legal costs after 2024 layoffs (www.biospace.com).
With a leaner cost base, Shattuck’s net loss for 2025 improved to $48.8 million (–$0.70 per share) from a $75.4 million loss (–$1.49) in 2024 (www.globenewswire.com). On a quarterly basis, Q4’s $12.6 M loss was a notable improvement year-on-year as mentioned. It’s worth noting these net losses include no revenue offset – Shattuck had zero product or collaboration revenue in 2025 (its drug candidates are still in trials). The only income would be modest interest on its cash investments, but clearly not enough to offset R&D spending.
Cash Burn & AFFO/FFO: Traditional cash flow metrics like Funds From Operations (FFO) or Adjusted FFO (AFFO) are not applicable here, as Shattuck has no operating cash inflows. Instead, the relevant metric is cash burn (operating loss plus working capital). In 2025, operating cash burn roughly equaled the $48.8 M net loss (plus/minus timing differences). Shattuck’s reduced burn rate (down from ~$75 M in 2024) reflects its cost discipline post-restructuring. The company’s ability to sustain operations rests on external financing rather than internal cash generation. Thus, dividend or FFO coverage ratios don’t apply – there are no dividends or positive funds from operations to cover. The company is not cash-flow-positive, and won’t be until it achieves a successful drug commercialization years down the line (if ever). For now, investors should track R&D spend vs available cash (runway) as a proxy for its financial health.
Balance Sheet, Leverage & Liquidity
Cash Position: Despite ongoing losses, Shattuck ended 2025 with a cash and short-term investments balance of $78.1 million (www.biospace.com), slightly above the $73.0 M it held a year prior (ir.shattucklabs.com). How did cash increase despite the $48.8 M annual loss? The answer is substantial new financing. In August 2025, Shattuck raised capital through a private placement led by OrbiMed Advisors, bringing in net proceeds that (with potential warrant exercises) total up to $103 million (www.globenewswire.com). This deal (at a deeply discounted $0.87/share, plus warrants) injected much-needed cash to fund SL-325’s trials. Additionally, in Q1 2026 Shattuck tapped an At-The-Market (ATM) equity facility, selling new shares for gross proceeds of $21.4 million (www.biospace.com). As a result, cash on hand swelled to ~$94.5 million as of Feb 28, 2026 (unaudited) (www.biospace.com). This pro-forma cash includes the Q1 ATM raise and positions the company to finance operations beyond near-term trials.
Leverage and Debt: Shattuck carries no significant debt on its balance sheet – an important point for risk. The company’s total liabilities are small, consisting mostly of accounts payable and lease obligations (about $11 M in total current liabilities as of end-2024) (ir.shattucklabs.com). It has no outstanding bank loans or bonds, meaning no debt maturities to worry about. The absence of debt means interest expense is negligible and interest coverage ratios are a non-issue. Essentially, Shattuck is equity-funded: it relies on shareholder capital (and to a lesser extent, grants or partnerships if any) to fund R&D. This conservative balance sheet gives Shattuck financial flexibility, albeit at the cost of diluting shareholders with new equity when cash is needed.
Liquidity & Runway: Management has guided that the current cash is sufficient to fund operations into 2029, assuming the outstanding warrants from the 2025 financing are fully exercised (www.globenewswire.com). This implies a multi-year runway, which is relatively long for a biotech at Shattuck’s stage. In fact, including the ATM raise and potential warrant proceeds, the company believes it can finance Phase 2 trials and beyond without additional financing till 2029 (www.globenewswire.com). However, that assumption hinges on warrant exercises (likely bringing in tens of millions in extra cash when holders exercise). If the stock stays high enough, warrant holders (including OrbiMed) have incentive to exercise, effectively injecting capital. If not, Shattuck might eventually need alternate funding. As of now, though, liquidity appears solid: the cash on hand (~$94 M) should comfortably cover the planned Phase 1 completion and upcoming Phase 2 trial initiation. In 2025, the quarterly cash burn averaged ~$12 M, so even if expenses ramp up in Phase 2, Shattuck seems financed for at least 3+ years. This solvency outlook is a positive, reducing near-term bankruptcy risk – a key consideration in small biotech investing.
Valuation & Analyst Coverage
Market Valuation: After a roller-coaster 2025, STTK’s stock has rebounded strongly. From 52-week lows around $0.69 per share in mid-2025 (www.marketbeat.com), the stock surged to around $3.50–$4.00 in early 2026. At ~$3.8 per share (recent price range), Shattuck’s market capitalization is roughly in the $400 million ballpark. With ~$94 M in cash, the enterprise value (EV) – i.e. the implied value of its pipeline and other assets – is about $300 M. Traditional valuation metrics are difficult to apply: Shattuck has no earnings (P/E is negative), and no steady cash flow for metrics like EV/EBITDA or P/FFO. In fact, the company is expected to remain unprofitable for many years as it funds R&D. Wedbush Securities, which initiated coverage in Sept 2025, forecast continued net losses through at least 2028 (e.g. projecting –$0.32 EPS in 2026 and still –$0.27 in 2028) (www.marketbeat.com). This underscores that any valuation is based on future potential, not current financials. At a ~$300 M EV, the market is assigning significant value to SL-325’s prospects – essentially betting that it could be an effective IBD therapy in a multi-billion dollar market. By comparison, note that Prometheus Biosciences (developer of a TL1A antibody for IBD) was acquired by Merck for $10.8 billion in 2023 (www.merck.com) (www.merck.com). Shattuck’s ~$300 M EV is a tiny fraction of that, reflecting its earlier stage and higher risk – but also the upside if SL-325 eventually proves to approach Prometheus’s success.
Analyst Sentiment: Wall Street coverage on STTK is modest but generally optimistic. Wedbush initiated coverage at Outperform with a $4.00 price target (www.marketbeat.com), citing confidence in Shattuck’s novel DR3 strategy. Other analysts also see upside: as of late 2025, the consensus rating was “Moderate Buy” with two Strong Buys, two Buys, and three Hold ratings (www.marketbeat.com). The average price target was about $4.00 per share (www.marketbeat.com), roughly in line with the current trading level. This implies the stock’s recent rally has already met analysts’ baseline expectations, potentially balancing risk/reward at this price. Notably, Needham had rated Hold (neutral) (www.marketbeat.com), indicating some stay on the sidelines pending more data, while Leerink Partners (SVB) even cut its target from $4 to $2 back in August 2025 (www.marketbeat.com) when uncertainty was high. However, that was before the successful financing and trial progress – since then sentiment improved, as evidenced by upgrades (even the crowd-sourced WallStreetZen moved its rating up to “hold” from sell (www.marketbeat.com)). Overall, the street acknowledges Shattuck’s promising science but is cautious given the early stage.
Institutional Investors: It’s worth highlighting the involvement of sophisticated biotech investors, which lends credibility to Shattuck’s valuation. The August 2025 financing was led by OrbiMed Advisors, a top-tier life sciences fund (www.globenewswire.com). OrbiMed’s affiliates (including board member Dr. Mona Ashiya) purchased over 6.3 million shares at $0.87 in that round (www.marketbeat.com), signaling conviction at a distressed moment for the company. OrbiMed also secured a board seat, aligning their interests with shareholders. In addition, T. Rowe Price disclosed taking over a 10% stake in early 2026 after participating in the ATM sales (www.biospace.com). Such institutional sponsorship suggests that knowledgeable investors see long-term value in Shattuck – a positive sign. These holders provide patient capital and industry expertise, which can support the stock’s valuation through the ups and downs of drug development.
Key Risks and Challenges
Every early-stage biotech like Shattuck Labs faces substantial risks. Investors should be aware of the following:
- Clinical & Regulatory Risk: SL-325 has not yet demonstrated efficacy in patients. Its upcoming Phase 1 readout will mainly show safety and target engagement, but there is no guarantee that blocking DR3 will translate into clinical benefits for Crohn’s or ulcerative colitis. The mechanism, while scientifically compelling, is unproven in humans. Drugs targeting similar pathways could fail due to unforeseen safety issues or lack of sufficient efficacy. If SL-325’s trial data disappoint (e.g. safety signals or weak pharmacodynamics), Shattuck’s entire thesis would be jeopardized. Even assuming good Phase 1 results, the Phase 2 Crohn’s trial in 2026 will be the real test – it must show meaningful improvement in patient outcomes. Any setback or trial delay could have a severe impact on the stock.
- Single Asset Dependence: After discontinuing its prior program, Shattuck is essentially a one-product company. The vast majority of its future value rides on SL-325. This concentration risk means that an adverse outcome for SL-325 (trial failure, regulatory hold, etc.) would leave the company with little else in the pipeline (aside from early-stage bispecific projects). Many biotech firms hedge risk by developing multiple candidates in parallel; Shattuck’s strategy, however, is heavily focused on one mechanism (the DR3/TL1A axis). That heightens the stakes – and volatility – for STTK investors.
- Competition & Market Risk: The immunology/IBD treatment space is highly competitive and evolving. Notably, big pharma is aggressively targeting the TL1A pathway – Shattuck’s indirect competition. Merck’s $10.8 B acquisition of Prometheus Biosciences in 2023 brought in PRA023, a TL1A-blocking antibody that is now in Phase 3 trials (www.merck.com). By the time Shattuck’s SL-325 could reach market (likely years away), established competitors may already be launching TL1A drugs. Merck’s candidate (now called MK-7240) and others could become entrenched if they show strong Phase 3 results. Shattuck believes targeting DR3 (the receptor) might yield more complete pathway blockade than targeting TL1A (the ligand) (www.globenewswire.com), but this hypothesis must be proven clinically. There is a risk that SL-325, even if successful, could be “late to market” or not clearly superior to first-to-market TL1A therapies. Competing against pharma giants in IBD would also require significant resources or a partnership. Moreover, other mechanism competitors (e.g. integrin therapies like Morphic’s MORF-057 in ulcerative colitis, or JAK/TYK2 inhibitors) are advancing – the bar for a new IBD drug is high. If SL-325’s profile isn’t differentiated, payers and physicians may favor the incumbents.
- Financial & Dilution Risk: While Shattuck has a healthy cash runway now, it remains contingent on future funding events. The 2025 private placement included warrants – full funding into 2029 assumes warrant exercise (www.globenewswire.com). Those warrants will only inject cash if exercised (likely when STTK’s market price is comfortably above the exercise price). Should the stock stagnate or fall below those thresholds, the company might not realize that anticipated capital. In that case – or if Shattuck decides to accelerate programs or start expensive Phase 3 studies – additional funding could be needed well before 2029. Any new equity financing would dilute shareholders further. Investors have already been diluted heavily (share count has roughly doubled in the last year through financing). If SL-325 shows promise, Shattuck may raise more capital to fund larger trials or commercialization, which could pressure the stock. Conversely, if the stock drops significantly, raising capital becomes harder (as seen in 2025 when shares hit $0.69 and the company had to sell equity at $0.87 (www.marketbeat.com)). Maintaining Nasdaq listing (trading above $1) is also a consideration – though currently the stock is comfortably above that, a collapse on bad news could re-introduce delisting risk. In short, Shattuck’s survival hinges on external capital, and shareholders bear the risk of future dilution.
- Execution & Regulatory Hurdles: Even with sufficient cash, Shattuck must execute clinical trials efficiently. Trial execution risk includes enrolling patients on time, meeting endpoints, and handling any FDA regulatory requirements. IBD trials can be challenging – placebo effects and variability in disease course can obscure results. Any delays in the Phase 2 trial (planned Q3 2026 start) or difficulties in scaling up manufacturing for a biologic drug could slow the path to market. Additionally, regulatory standards for safety are high given prior safety issues with some immunomodulators. There’s always risk that regulators could request larger or additional studies, especially since DR3 blockade is novel.
- Macroeconomic & Market Conditions: Broader conditions can affect Shattuck’s risk. Rising interest rates and risk-off investor sentiment can particularly hurt pre-revenue biotech valuations. If capital markets tighten, even a company with Shattuck’s runway might find it difficult to raise money on favorable terms in the future. Also, high inflation in trial costs or talent retention challenges could increase burn rate. While not company-specific, these factors can influence how easily Shattuck can navigate its long development road.
Red Flags for Investors
While the above are general risks, a few red flags stand out in Shattuck’s recent history that investors should note:
- Heavy Insider Dilution at Low Prices: The financing in 2025, though lifesaving for the company, came at a steep cost to existing shareholders. Shattuck sold a large block of equity at $0.87 per share, a price ~80% below the stock’s initial 2021 trading levels and even below cash value (www.marketbeat.com) (www.marketbeat.com). OrbiMed and other participants obtained cheap shares plus warrants, significantly diluting earlier investors. The fact that the company’s situation became dire enough to require such a dilutive down-round is a cautionary sign. It suggests prior management optimism fell short, and raises questions about whether further dilution could occur if things don’t go as planned. Current shareholders should monitor the use of the ATM facility or any new financing proposals closely. The presence of robust cash now mitigates this in the near term, but it’s a red flag in the company’s recent past.
- Previous Program Termination: Shattuck’s decision to terminate SL-172154 (an oncology program) in 2024 indicates a major strategic pivot (ir.shattucklabs.com). This could be viewed two ways: prudent capital allocation (cutting losses on a program that wasn’t meeting benchmarks), or a red flag that the company’s initial platform did not pan out. Investors may worry whether SL-325, a newer bet, will fare differently. The failure of SL-172154 (which had been in clinical trials for cancer) underscores the unpredictable nature of biotech R&D. It also means Shattuck invested significant resources in a program that ultimately added no value, which is concerning. The lack of any partnership or out-licensing for that asset (it was simply discontinued) might hint that it had little salvageable merit. While the pivot to DR3/IBD is based on a sound scientific rationale, the company’s track record took a hit with the previous program’s collapse.
- High Stock Volatility & Low Market Cap History: STTK’s stock price history shows extreme volatility. It traded over $4 shortly after IPO, then crumbled to penny-stock territory (<$1) by mid-2025, before quadrupling within months. Such swings can be a red flag for speculative trading and unstable investor confidence. The dip below $1 could have even led to Nasdaq compliance issues. Although the price recovered, the stock’s low float and heavy retail trading (1.6 M avg volume vs ~100 M float) (www.marketbeat.com) have made it prone to big moves. Investors should be prepared for high volatility around news events. A low market capitalization (~$90 M at one point (www.marketbeat.com)) also meant the stock was at risk of being overlooked by major funds or even potential hostile takeover when it was very cheap. Now with a higher cap, those specific risks recede, but volatility remains a concern.
- Reliance on Key Personnel: Shattuck is a small company, and its success leans on a few key scientists and executives (e.g. CEO Dr. Schreiber). The addition of Dr. Dan Baker and Dr. Mona Ashiya to the board in 2025 brought valuable expertise (Dr. Baker helped develop Remicade/Stelara at J&J) (www.globenewswire.com). However, the simultaneous departure of four board members in that reshuffle (www.globenewswire.com) could indicate past strategic disagreements or investor pressure. Sudden turnover in management or board can be a red flag if it signals internal turmoil. Thus far there’s no open indication of trouble, but stability of the team is something to watch. With lean staffing, losing any key scientist or the chief medical officer could slow development. Overall, while not an acute red flag now, governance and leadership changes bear attention given the company’s pivot.
Despite these flags, it’s important to contextualize them. The dilution and program cut were part of a necessary strategy shift that may have saved the company, and new investors/board members could be a positive catalyst. Nonetheless, potential investors should weigh these cautionary signs in their due diligence.
Outlook and Open Questions
Shattuck Labs is entering a pivotal period in 2026. Key data and decisions in the next 12–18 months will likely determine the company’s trajectory. Here are some open questions that remain:
- Will SL-325’s Phase 1 data affirm the drug’s potential? In the coming quarter, Shattuck will report first-in-human results for SL-325. Investors are eager to see if the antibody demonstrates a clean safety profile (no significant adverse effects or immunogenicity) and achieves the desired receptor occupancy on DR3 (www.globenewswire.com). These results will guide the dosing for Phase 2. If any safety red flags emerge or the target engagement is weaker than expected, it could delay or derail the Phase 2 start. Conversely, solid Phase 1 data would validate Shattuck’s preclinical findings and de-risk the mechanism, potentially attracting more investor or partner interest.
- How will the design and execution of the Phase 2 Crohn’s trial play out? Assuming Phase 1 is positive, Shattuck plans to initiate a Phase 2 trial in Crohn’s disease by Q3 2026 (www.globenewswire.com). Open questions include: What patient population and endpoints will they choose? Will they test SL-325 in moderate-to-severe Crohn’s patients who are inadequate responders to existing biologics? The trial needs to be robust enough to demonstrate efficacy against placebo. Also, will it be placebo-controlled and potentially multi-country, or a smaller proof-of-concept study? Successful enrollment and execution will be crucial – any delays (e.g. due to patient recruitment challenges) could push timelines. We also wonder if ulcerative colitis trials will follow; the press release suggests Crohn’s first, but DR3 is relevant in UC too. Clarity on the breadth of Phase 2 plans is anticipated.
- Can Shattuck differentiate DR3-blockade from TL1A-blockade clinically? A central thesis for Shattuck is that targeting DR3 (the receptor) could be superior to targeting TL1A (the ligand) in IBD (www.globenewswire.com). This is based on achieving more complete pathway inhibition and possibly reduced off-target effects. An open question is whether this theoretical advantage will manifest in patient outcomes. Will SL-325 produce higher remission rates or longer-lasting responses than TL1A antibodies like Merck’s? It may be hard to directly compare without head-to-head trials, but biomarkers or cross-trial comparisons might hint at differences. If SL-325 only matches the efficacy of TL1A inhibitors, its late entry could limit its adoption. Shattuck might need to emphasize any superior aspects (e.g. better mucosal healing, safety in certain patient subsets, etc.). Until clinical data is available, this question mark will hang over the program.
- What is the second target in Shattuck’s bispecific program – and what is the plan for it? The company has teased a bispecific antibody that inhibits both DR3/TL1A and another “biologically relevant target” for inflammatory disease (www.globenewswire.com). By mid-2026, Shattuck intends to unveil the target(s) and supporting preclinical data. An open question is: which pathway have they chosen to pair with DR3, and why? Perhaps it’s another cytokine or co-stimulatory pathway implicated in IBD (examples could be integrins, IL-13, IL-23, etc.). The identity will tell us how innovative or competitive this bispecific could be. Moreover, what is the timeline? Will it enter the clinic in 2027 or later? This bispecific could diversify Shattuck’s pipeline beyond SL-325, but until details emerge, it’s an unknown. Investors will be watching the upcoming disclosure – it could add value if the science is compelling, or be met with skepticism if it appears too early-stage or outside Shattuck’s core focus.
- Is a partnership or collaboration on the horizon? To date, Shattuck has not announced any major pharma partnerships for SL-325 or its platform. Many small biotechs will seek a larger partner to co-develop or commercialize a drug – especially for something like IBD where Phase 3 trials and marketing are very costly. A question is whether Shattuck will continue to go it alone through Phase 2, or try to secure a partner if Phase 2 data are positive. Partnering could provide non-dilutive funding and expertise (e.g. leveraging a big pharma’s IBD trial experience), but it might require giving up rights or profit share. Shattuck’s healthy cash position implies it doesn’t need a partner immediately to fund Phase 2. They may prefer to retain full ownership through proof-of-concept, hoping to command a higher valuation later (much like Prometheus did, selling at Phase 2 success for $10B+). However, if a partnership opportunity arises (say, a mid-size pharma interested in DR3 pathway), it could accelerate development or expand indications. This remains an open strategic question: will Shattuck seek a partnership after Phase 1 or Phase 2, or only consider outright acquisition offers? Management’s moves in 2026–27 will shed light on this.
- Will the full funding “into 2029” truly materialize? Management’s guidance that cash will last into 2029 assumes that all outstanding warrants get exercised for cash (www.globenewswire.com). Those warrants likely correspond to millions of shares at set strike prices (details not publicly in the press release). An open question is, under what conditions will these be exercised? If the stock stays well above the strike price for an extended period, one expects holders (including OrbiMed) to exercise and perhaps even sell some shares, providing the company cash. But if the stock underperforms or the warrants are long-dated, there’s uncertainty. It’s possible Shattuck could also consider alternative funding – for instance, debt financing or additional ATM usage – if the environment is right. While 2029 runway is optimistic, prudent investors might assume a shorter runway unless warrant conversion is virtually assured. Tracking the warrant count, strikes, and any exercises (which would be reported via SEC filings) is thus an open item. In essence, is Shattuck truly funded into 2029 as they say, or will cash needs hit sooner? The answer depends on both stock performance and management’s spending plans (e.g. if they start multiple Phase 2 trials or a Phase 3, the burn could increase).
- How will the competitive landscape evolve by the time Shattuck’s data matures? This is a broader question that will define Shattuck’s ultimate opportunity. By 2027 or 2028, when SL-325 might be nearing Phase 3 or pivotal data, what will Merck’s TL1A drug status be? Will other novel IBD therapies (e.g. a new oral drug or cell therapy) emerge as serious competitors? The IBD market is crowded with approved biologics (anti-TNFs, IL-12/23 blockers, integrin blockers, JAK inhibitors) and many in development. Shattuck’s fortunes may depend on securing a place in the future treatment paradigm. Open questions include whether DR3-blockade might work in patients who don’t respond to TL1A blockers – if yes, SL-325 could carve out a niche even if it’s second to market. Or, could SL-325 have synergy with other treatments? The competitive dynamics are fluid. Investors should watch for data readouts from competitors (e.g. Merck’s Phase 3 TL1A results expected likely in 2024/25, Morphic’s Phase 2 UC results, etc.) as those will frame expectations for SL-325’s bar for success.
In conclusion, Shattuck Labs has navigated a challenging 2025 by restructuring and securing funding, and now stands on the cusp of critical clinical milestones in 2026. The Q4 and full-year 2025 results show a company that cut costs and shored up its balance sheet to give itself a fighting chance in the quest for a first-in-class IBD therapy. With a strong cash runway, clear focus, and credible investors backing it, STTK offers a high-risk, high-reward profile. The coming year will begin to answer whether Shattuck’s DR3 strategy validates the hype. Investors shouldn’t “miss out” on closely following those developments – but they should do so with eyes open to the significant risks outlined. As data rolls in, STTK’s valuation will adjust accordingly, and we’ll learn if this small-cap biotech can transform its bold scientific thesis into tangible clinical success. The next few quarters could be game-changing for Shattuck, one way or the other. Stay tuned.
Sources:
1. Shattuck Labs – Q4 and FY2025 Earnings Press Release (financial results, pipeline updates, March 5, 2026) (www.globenewswire.com) (www.globenewswire.com) (www.biospace.com). 2. Shattuck Labs – Q4 and FY2024 Earnings Press Release (context on 2024 restructuring and SL-172154 termination, March 27, 2025) (ir.shattucklabs.com) (ir.shattucklabs.com). 3. BioSpace – Shattuck Labs Reports Q4/FY2025 Results (press release repost, highlights of SL-325 trial progress and ATM financing, March 5, 2026) (www.biospace.com) (www.biospace.com). 4. MarketBeat – Wedbush Initiation and Analyst Forecasts for STTK (analyst ratings, price target, and insider transactions, Sept 8, 2025) (www.marketbeat.com) (www.marketbeat.com) (www.marketbeat.com). 5. GlobeNewswire – Shattuck $103 M Private Placement Announcement (details on Aug 2025 financing led by OrbiMed, cash runway into 2029, Aug 26, 2025) (www.globenewswire.com) (www.globenewswire.com). 6. Merck Press Release – Merck’s Acquisition of Prometheus Biosciences (TL1A antibody PRA023 in IBD acquired for $10.8 B, competitive landscape, April 16, 2023) (www.merck.com) (www.merck.com). 7. Alpha Spread – Shattuck Labs Dividend and Shareholder Info (confirmation that STTK has no dividend history) (www.alphaspread.com). 8. Shattuck Labs SEC Filing (Form 10-Q Q3 2025) – Risk Factors & Financials (analysts noted Needham hold, Leerink target cut on Aug 14, 2025, reflecting past concerns) (www.marketbeat.com). (Used for context on sentiment shifts.) 9. StockAnalysis – STTK Price History 2025-2026 (trading range data, 52-week low/high and volumes, illustrating volatility) (www.marketbeat.com).
